Breaking News Instant updates and real-time market news.

CTAS

Cintas

$253.61

-5.78 (-2.23%)

, BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

18:42
11/21/19
11/21
18:42
11/21/19
18:42

Jefferies initiates Diversifed Services sector

Jefferies analyst Hamzah Mazari initiated select names across Diversified Services as part of his broader research note covering the Business Services industry. The analyst has a Buy rating on Cintas (CTAS) with a $308 price target, Bright Horizons (BFAM) with a $177 price target, BrightView (BV) with a $23 price target, and ServiceMaster (SERV) with a $43 price target. Mazari likes the M&A potential and employment decoupling at Cintas, revenue growth visibility and cross selling opportunity at Bright Horizons, low organic growth expectations and free cash flow potential at BrightView, and underappreciated international growth opportunity at ServiceMaster. The analyst also rates Aramark (ARMK), H&R Block (HRB), and Rollins (ROL) at Hold with respective $49, $28, and $38 price targets, noting that Aramark expectations are "too high" on activist involvement, H&R Block suffers from lack of catalysts, and Rollins' M&A potential appears to be "baked in" to its valuation.

CTAS

Cintas

$253.61

-5.78 (-2.23%)

BFAM

Bright Horizons

$148.62

-3.92 (-2.57%)

ARMK

Aramark

$42.42

-1.37 (-3.13%)

HRB

H&R Block

$24.34

-0.15 (-0.61%)

BV

BrightView

$16.79

-2.525 (-13.08%)

ROL

Rollins

$35.77

-0.8 (-2.19%)

SERV

ServiceMaster

$36.16

-0.42 (-1.15%)

  • 21

    Nov

  • 04

    Dec

CTAS Cintas
$253.61

-5.78 (-2.23%)

11/21/19
JEFF
11/21/19
INITIATION
Target $308
JEFF
Buy
Cintas initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Cintas with a Buy rating and $308 price target.
11/13/19
JPMS
11/13/19
NO CHANGE
JPMS
Overweight
Cintas management offers responses to short report's questions to JPMorgan
JPMorgan analyst Andrew Steinerman noted that a short report published this morning raised questions around fraudulent practices within Cintas' Fire Protection Services business. While he noted that Cintas management had not yet read the short report when he spoke with them, he said that company management indicated that there are no systemic issues of improper inspections or licensing practices and that they are confident in the policies and procedures in place. Responding to questions around fast growing accounts receivable recently, management said that the combination of SAP conversion and the large GK acquisition make it only natural that receivables are impacted. On questions of allegedly worsening cash collections, management responded that the low rates on commercial paper rates have been compelling and driving usage of short-term financing recently, Steinerman added. He has an Overweight rating on Cintas shares.
11/13/19
BARD
11/13/19
NO CHANGE
Target $300
BARD
Outperform
Baird says Cintas short report 'weak and flawed,' recommends adding to positions
Baird analyst Andrew Wittmann said short-seller Spruce Point presented "a series of weak and flawed arguments which demonstrate poor understanding of the business model and the industry" in its report published this morning targeting Cintas. Of the five key topics of concern raised by Spruce Point, Wittmann said the only one he would not argue against is the stock's elevated valuation, as the shares recently have hit record valuations, but he adds that "You get what you pay for." On the allegations of fraudulent labor practices, Wittmann argues that Spruce Point is extrapolating a single inspection citation, which was an isolated incident, in a way that "succumbs to the anecdotal evidence fallacy." The analyst recommends adding to positions on any weakness and keeps an Outperform rating on Cintas with a $300 price target.
09/25/19
BARD
09/25/19
NO CHANGE
Target $300
BARD
Outperform
Cintas price target raised to $300 from $267 at Baird
Baird analyst Andrew Wittmann raised his price target on Cintas to $300 from $267 following solid Q1 results. The analyst raised his estimates as the company continues to win in the marketplace, fundamentals remain solid, and the beat-and-raise pattern will likely continue. Wittmann reiterated his Outperform rating on Cintas shares.
BFAM Bright Horizons
$148.62

-3.92 (-2.57%)

10/08/19
MSCO
10/08/19
INITIATION
Target $162
MSCO
Equal Weight
Bright Horizons initiated with an Equal Weight rating at Morgan Stanley
Morgan Stanley analyst Toni Kaplan initiated coverage of Bright Horizons with an Equal Weight rating and $162 price target. She sees the company's subscription-based business model as differentiated and notes its 95% customer retention, but Kaplan thinks the market is already giving Bright Horizons credit for its "best-in-class positioning" and would advise waiting for a better entry point into the stock.
09/11/19
BMOC
09/11/19
UPGRADE
Target $166
BMOC
Outperform
Bright Horizons upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Jeffrey Silber upgraded Bright Horizons to Outperform from Market Perform and raised his price target for the shares to $166 from $152. The recent pullback in the shares is overdone given the company's "strong position" in the current environment, Silber tells investors in a research note. The analyst highlights the tight labor market, beneficial secular trends, including encouraging women in the workforce, and Bright Horizons' "resiliency in a downturn" given its pricing power. He believes the company should be a core holding in any investment portfolio.
07/10/19
BMOC
07/10/19
NO CHANGE
Target $152
BMOC
Market Perform
Bright Horizons price target raised to $152 from $130 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on Bright Horizons to $152 as part of his broader research note previewing Q2 results for private education providers. The analyst says the stock is among the best-run and best-positioned companies to benefit from childcare services growth given the tight labor market and the improvement in the demographic backdrop. Silber keeps his Market Perform rating on Bright Horizons shares.
11/21/19
JEFF
11/21/19
INITIATION
Target $177
JEFF
Buy
Bright Horizons initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Bright Horizons with a Buy rating and $177 price target.
ARMK Aramark
$42.42

-1.37 (-3.13%)

11/21/19
JEFF
11/21/19
INITIATION
Target $49
JEFF
Hold
Aramark initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Aramark with a Hold rating and $49 price target.
11/15/19
GDHS
11/15/19
NO CHANGE
GDHS
Gordon Haskett says Ackman, Icahn could be buyer behind Nomura's Netflix stake
Don Bilson, who heads Gordon Haskett's event-driven research team, said in a note prior to the open that Nomura's largest stock purchase last quarter was Netflix (NFLX), noting that the Japanese bank "put Mantle Ridge into Aramark (ARMK) and Carl Icahn into HP (HPQ) via a swap or some sort of options trade that remained on Nomura's books" previously. He speculated Bill Ackman could be the buyer behind Nomura's stakeholding, even "though there is nothing for an activist to do" at Netflix, given it fits the pattern of some other Pershing Square stock investments and Ackman mentioned not long ago that he had built a new, unnamed position. If it's not Ackman, "we suppose it could be Carl Icahn who just proved he knows who to call at Nomura" and his son, who previously got Icahn into the stock, is set to rejoin his fund shortly, Argenti wrote in his pre-open note.
11/15/19
STFL
11/15/19
NO CHANGE
Target $49
STFL
Buy
Aramark quarter 'could be sloppy' given recent activist shakeup, says Stifel
Stifel analyst Shlomo Rosenbaum said he would not be surprised if Aramark's Q4 "numbers are sloppy" given the activist investor stake announcement that resulted in a change of board composition, exit of the prior CEO and hiring of a new CEO during the quarter. Though it might be early for a new CEO to put forth his new operating plan, Rosenbaum thinks the focus should be on the room for improvement, he stated. When John Zillmer does put forth his plan, Rosenbaum expects it to be "solid" with a focus on allocating capital to the appropriate areas, the analyst added, leading him to maintain a Buy rating and $49 price target on Aramark shares.
10/01/19
BOFA
10/01/19
NO CHANGE
BOFA
Top 10 US Ideas for Q4 at BofA/Merrill
BofA/Merrill introduced the Top 10 US Ideas for Q4 2019. The list's seven Buys are Aramark (ARMK), Salesforce (CRM), Disney (DIS), Dover (DOV), New York Community Bancorp (NYCB), Raytheon (RTN), and Target (TGT). Underperform's are Floor & Decor (FND), Gap (GPS), and Terex (TEX).
HRB H&R Block
$24.34

-0.15 (-0.61%)

07/09/19
NRCS
07/09/19
DOWNGRADE
NRCS
Neutral
H&R Block downgraded to Neutral from Buy at Northcoast
Northcoast analyst Kartik Mehta downgraded H&R Block to Neutral from Buy.
11/21/19
JEFF
11/21/19
INITIATION
Target $28
JEFF
Hold
H&R Block initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of H&R Block with a Hold rating and $28 price target.
08/30/19
BRRR
08/30/19
NO CHANGE
BRRR
H&R Block price target lowered to $30 from $32 at Barrington
Barrington analyst Alexander Paris Jr. maintained an Outperform rating on H&R Block, but lowered his price target on the shares to $30 from $32. H&R Block reported Q1 EPS and revenue that were better than expected, and reaffirmed its FY20 financial guidance. Additionally, the analyst noted that H&R Block completed its acquisition of Wave HQ, which is expected to contribute $40M-45M of revenue in FY20.
11/08/19
BMOC
11/08/19
NO CHANGE
Target $25
BMOC
Market Perform
H&R Block stock drop may be due to confusion over PR, says BMO Capital
BMO Capital analyst Jeffrey Silber says H&R Block's over 5% stock decline on Friday may be due to the press release announcing that the company's DIY software product for the upcoming tax season is now available for sale. Silber, who has a Market Perform rating and $25 price target on the stock, says that while more detailed pricing information is provided relative to last year's release, he does not believe prices are meaningful different for the product line.
BV BrightView
$16.79

-2.525 (-13.08%)

07/18/19
JPMS
07/18/19
DOWNGRADE
Target $18
JPMS
Neutral
JPMorgan downgrades BrightView to Neutral on near-term caution
JPMorgan analyst Judah Sokel downgraded BrightView Holdings to Neutral from Overweight with an unchanged $18 price target. The analyst remains positive on the company's longer term potential, but he sees risk to estimates and prefers moving to the sidelines after the stock's year-to-date run of 75%. He's cautious in the near-term about BrightView's fiscal Q3 results. A strong May rain season likely created a challenging environment for maintenance ancillary work and development projects, Sokel tells investors in a research note. He also senses a possible secondary on the horizon following the company's recent shelf registration.
07/18/19
JPMS
07/18/19
DOWNGRADE
Target $18
JPMS
Neutral
BrightView downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Judah Sokel downgraded BrightView Holdings to Neutral from Overweight with an $18 price target.
07/18/19
07/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) and Skyworks (SWKS) downgraded to Equal Weight from Overweight at Barclays. 2. AMD (AMD) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying he continues to like AMD given its "solid" Ryzen/Rome portfolio and new product ramps, but he's downgrading the shares after a "stellar" 80% rally year-to-date. 3. BrightView (BV) downgraded to Neutral from Overweight at JPMorgan with analyst Judah Sokel saying he remains positive on the company's longer term potential, but he sees risk to estimates and prefers moving to the sidelines after the stock's year-to-date run of 75%. 4. MGM Resorts (MGM) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Thomas Allen saying he is concerned that Vegas, Macau, and its U.S. regional properties are all going to come in below his prior expectations. 5. Exxon Mobil (XOM) and Vermilion Energy (VET) downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/19
JEFF
11/21/19
INITIATION
Target $23
JEFF
Buy
BrightView assumed with a Buy at Jefferies
Jefferies analyst Hamzah Mazari assumed coverage of BrightView with a Buy rating and $23 price target.
ROL Rollins
$35.77

-0.8 (-2.19%)

11/21/19
JEFF
11/21/19
INITIATION
Target $38
JEFF
Hold
Rollins initiated with a Hold at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of Rollins with a Hold rating and $38 price target.
11/06/19
11/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Rollins (ROL) upgraded to Hold from Sell at Stifel with analyst Michael Hoffman saying the company has "reinvigorated" organic growth and when combined with more rapid consolidation of domestic Pest Control, it can likely drive double digit free cash flow growth for the next five years. 2. Tenet (THC) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he "solid trends" in the company's hospital business, including improving volumes, steady pricing growth, and "effective management" of underlying cost growth. 3. Blueprint Medicines (BPMC) upgraded to Strong Buy from Outperform at Raymond James with analyst Dane Leone citing the company's R&D update in NYC. 4. Lowe's (LOW) upgraded to Outperform from Neutral at Credit Suisse with analyst Seth Sigman saying the company's relative valuation versus closest peer Home Depot (HD) is near its trough level, industry demand is improving and there are "multiple sales/margin levers ahead." 5. Artisan Partners (APAM) upgraded to Buy from Neutral at Citi with analyst William Katz saying he sees potential for the company's net new assets to inflect positively into 2021, which he thinks should be enough to drive modest multiple expansion. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/06/19
STFL
11/06/19
UPGRADE
Target $34
STFL
Hold
Rollins upgraded to Hold from Sell at Stifel
Stifel analyst Michael Hoffman upgraded Rollins to Hold from Sell with a price target of $34, up from $26.50. The company has "reinvigorated" organic growth and when combined with more rapid consolidation of domestic Pest Control, it can likely drive double digit free cash flow growth for the next five years, Hoffman tells investors in a research note. The analyst cites better near-term free cash flow prospects for his upgrade to Hold.
10/08/19
RBCM
10/08/19
INITIATION
Target $34
RBCM
Sector Perform
Rollins initiated with a Sector Perform at RBC Capital
RBC Capital analyst Seth Weber initiated Rollins (ROL) with a Sector Perform rating and a price target of $34. The analyst is positive on the company's position in the "attractive" U.S. pest control market along with its "impressive" growth track record and outperformance relative to the S&P over the long and the short term. Despite the company's healthy balance sheet and growing cash flows however, Weber notes that the valuation on the stock "does not leave much wiggle room" as it currently trades at an 8-turn premium on enterprise value to EBITDA multiple basis relative to its pest peer ServiceMaster (SERV).
SERV ServiceMaster
$36.16

-0.42 (-1.15%)

11/21/19
JEFF
11/21/19
INITIATION
Target $43
JEFF
Buy
ServiceMaster initiated with a Buy at Jefferies
Jefferies analyst Hamzah Mazari initiated coverage of ServiceMaster with a Buy rating and $43 price target.
11/18/19
WBLR
11/18/19
NO CHANGE
WBLR
Outperform
ServiceMaster recent selloff presents buying opportunity, says William Blair
Since the company's Q3 prerelease on October 22, shares of ServiceMaster have declined 38%, erasing approximately $2.9B of market capitalization, William Blair analyst Tim Mulrooney tells investors in a research note. After speaking to investors, the analyst believes the primary reason for the pullback is related to the potential for "long-tailed" liabilities in the form of termite damage claims. Mulrooney sized the totality of claims and sees less than $150M related to Mobile, Alabama, which he notes is significantly less than what is implied by the recent market reaction. The current entry point is attractive and represents an opportunity for investors to own shares of a "well-capitalized market leader in the highly attractive pestcontrol industry," contends the analyst. He sees a buying opportunity at current share levels and maintains an Outperform rating on ServiceMaster.
11/06/19
RBCM
11/06/19
NO CHANGE
Target $54
RBCM
ServiceMaster price target lowered to $54 from $59 at RBC Capital
RBC Capital analyst Seth Weber lowered his price target on ServiceMaster to $54 in spite of its earnings beat, saying the company's damage claims costs of 7%-8% were above the historical average of 4%-4.5%. The analyst keeps his Outperform rating however and notes that the quarter is not "thesis changing", with much of the headwind coming in legacy operations and not Terminix, where trends are improving.
10/25/19
BUCK
10/25/19
NO CHANGE
Target $45
BUCK
Neutral
ServiceMaster price target lowered to $45 from $61 at Buckingham
Buckingham analyst James Clement lowered his price target for ServiceMaster to $45 from $61 and maintained a Neutral rating following this week's pre-announcement and guidance reduction. In a research note to investors, Clement says he is concerned that the termite situation could drag on in Alabama, which is among the most litigious pest control states in America, and says he does not think other pest control operators are facing the same claims pressure.

TODAY'S FREE FLY STORIES

SPT

Sprout Social

20:34
12/12/19
12/12
20:34
12/12/19
20:34
Syndicate
Sprout Social 8.824M share IPO priced at $17.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SCHW

Charles Schwab

$51.08

1.48 (2.98%)

20:16
12/12/19
12/12
20:16
12/12/19
20:16
Upgrade
Charles Schwab rating change at Keefe Bruyette »

Charles Schwab upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

Bluebird Bio

$84.00

-2.97 (-3.41%)

20:08
12/12/19
12/12
20:08
12/12/19
20:08
Upgrade
Bluebird Bio rating change at Oppenheimer »

Bluebird Bio upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$6.73

-0.97 (-12.60%)

20:07
12/12/19
12/12
20:07
12/12/19
20:07
Syndicate
Aquestive Therapeutics 7M share Secondary priced at $5.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BY

Byline Bancorp

$18.95

0.54 (2.93%)

19:56
12/12/19
12/12
19:56
12/12/19
19:56
Hot Stocks
Byline Bancorp initiates 3c per share cash dividend »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

NXGN

NextGen Healthcare

$16.83

-1.28 (-7.07%)

19:08
12/12/19
12/12
19:08
12/12/19
19:08
Downgrade
NextGen Healthcare rating change at Cantor Fitzgerald »

NextGen Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMOT

Allied Motion

$46.79

0.81 (1.76%)

18:57
12/12/19
12/12
18:57
12/12/19
18:57
Hot Stocks
Allied Motion CEO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

, DISCA

Discovery

$32.36

0.28 (0.87%)

18:54
12/12/19
12/12
18:54
12/12/19
18:54
Hot Stocks
Liberty Latin America says Dr. John Malone retires from board »

Liberty Latin America…

LILA

Liberty Latin America

$17.56

0.32 (1.86%)

DISCA

Discovery

$32.36

0.28 (0.87%)

LGF.A

Lionsgate

$9.99

0.65 (6.96%)

LGF.B

Lionsgate

$9.35

0.7 (8.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOCPY

Hoya Corp.

$0.00

(0.00%)

, TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

18:43
12/12/19
12/12
18:43
12/12/19
18:43
Hot Stocks
Hoya to offer JPY12,900 per share in tender offer for Toshiba unit NuFlare »

Hoya Corporation (HOCPY)…

HOCPY

Hoya Corp.

$0.00

(0.00%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

ADBE

Adobe

$305.76

2.01 (0.66%)

, SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:42
12/12/19
12/12
18:42
12/12/19
18:42
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$305.76

2.01 (0.66%)

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

DDOG

Datadog

$35.75

0.23 (0.65%)

RIG

Transocean

$5.94

0.28 (4.95%)

TPR

Tapestry

$26.35

0.515 (1.99%)

GTIM

Good Times Restaurants

$1.71

0.14 (8.92%)

ORCL

Oracle

$56.47

0.16 (0.28%)

AVGO

Broadcom

$327.39

7.53 (2.35%)

COST

Costco

$297.50

2.28 (0.77%)

CNC

Centene

$58.52

-0.13 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 23

    Jan

  • 23

    Mar

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:40
12/12/19
12/12
18:40
12/12/19
18:40
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta up 28.5% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$28.67

0.1 (0.35%)

18:38
12/12/19
12/12
18:38
12/12/19
18:38
Syndicate
Phreesia 6.75M share Secondary priced at $26.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:31
12/12/19
12/12
18:31
12/12/19
18:31
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta to resume trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

18:25
12/12/19
12/12
18:25
12/12/19
18:25
Hot Stocks
Adobe CEO: We are not overly concerned with the trade war with China »

Comment from interview…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:20
12/12/19
12/12
18:20
12/12/19
18:20
Hot Stocks
Sarepta announces FDA approval of VYONDYS 53 injection to treat DMD »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,760.44

11.33 (0.65%)

18:11
12/12/19
12/12
18:11
12/12/19
18:11
Hot Stocks
Amazon orders fourth season of 'The Marvelous Mrs. Maisel' »

Amazon Studios announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OHAI

OHA Investment

$1.28

(0.00%)

, PTMN

Portman Ridge Finance

$2.04

(0.00%)

18:10
12/12/19
12/12
18:10
12/12/19
18:10
Hot Stocks
OHA Investment obtains stockholder approval of Portman Ridge deal »

OHA Investment…

OHAI

OHA Investment

$1.28

(0.00%)

PTMN

Portman Ridge Finance

$2.04

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCT

Oncternal Therapeutics

$4.62

0.05 (1.09%)

18:05
12/12/19
12/12
18:05
12/12/19
18:05
Hot Stocks
Oncternal presents interim data from Phase 1b clinical study of cirmtuzumab »

Oncternal Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZN

Horizon Global

$3.49

0.14 (4.18%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Horizon Global CFO Jamie Pierson steps down »

Horizon Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

18:03
12/12/19
12/12
18:03
12/12/19
18:03
Hot Stocks
Oracle CEO Catz says expects momentum in 2H20 to carry into FY21 »

Says feels "very…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

18:00
12/12/19
12/12
18:00
12/12/19
18:00
Hot Stocks
Breaking Hot Stocks news story on Sarepta »

Sarepta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

17:52
12/12/19
12/12
17:52
12/12/19
17:52
Hot Stocks
Oracle's Ellison says 'we have no plans for having a second CEO' »

Says there won't be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

, EVRC

Evercel, Inc

$0.00

(0.00%)

17:41
12/12/19
12/12
17:41
12/12/19
17:41
Hot Stocks
NewLink Genetics advances over 11% after Evercel discloses rejected offer »

Shares of NewLink…

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

EVRC

Evercel, Inc

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRC

Evercel, Inc

$0.00

(0.00%)

, NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

17:36
12/12/19
12/12
17:36
12/12/19
17:36
Hot Stocks
Evercel announces rejected offer to acquire NewLink Genetics »

Evercel (EVRC) has made…

EVRC

Evercel, Inc

$0.00

(0.00%)

NLNK

NewLink Genetics

$1.61

-0.015 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXRX

Baudax Bio

$6.30

0.225 (3.70%)

17:34
12/12/19
12/12
17:34
12/12/19
17:34
Hot Stocks
Corsair Capital reports 8.77% passive stake in Baudax Bio »

Corsair Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.